. 2018 Jan 9;11:1756283X17745776. doi: 10.1177/1756283X17745776

Table 1.

pH > 4 holding time (%) with proton-pump inhibitors and potassium-competitive acid blockers.

PPI/P-CAB	Dose (mg)		Single-dose studies	Multiple-dose
Omeprazole^*	20		30.4	48.7 ± 20.5
Esomeprazole^*	20		32.5 ± 9.2	56.3 ± 7.4
	40		43.1 ± 17.8	64.6 ± 15.2
Lansoprazole^*	15		28.1 ± 10	45.9 ± 14.3
	30		39.1 ± 12.8	55.1 ± 14.4
Rabeprazole^*	10		29.8 ± 13.2	51.2 ± 13.1
	20		42.8 ± 15.9	57.7 ± 14.2
Revaprazan^#	150		39.4 ± 22.7	39.9 ± 17.0
	300		61.7 ± 14.2	65.6 ± 12.0
Vonoprazan^§	10	JP	38.4 ± 22.3	63.3 ± 8.7
		UK	43.1 ± 21.2	60.2 ± 19.1
	20	JP	63.3 ± 17.9	83.4 ± 16.7
		UK	62.7 ± 16.8	85.2 ± 12.3
	40	JP	85.3 ± 8.3	100 ± 00
		UK	85.6 ± 7.4	93.2 ± 10.5

Data obtained from healthy volunteers.²⁴

Data obtained in healthy males.²²

^§

Data obtained in healthy Japanese males or those in the UK.³⁴

JP, Japanese; UK, Subjects from the United Kingdom.